DANIELLI, RICCARDO
 Distribuzione geografica
Continente #
NA - Nord America 1.981
EU - Europa 1.386
AS - Asia 790
SA - Sud America 106
Continente sconosciuto - Info sul continente non disponibili 75
AF - Africa 32
OC - Oceania 1
Totale 4.371
Nazione #
US - Stati Uniti d'America 1.943
RU - Federazione Russa 379
SG - Singapore 329
IT - Italia 225
CN - Cina 223
GB - Regno Unito 220
IE - Irlanda 213
BR - Brasile 86
VN - Vietnam 84
DE - Germania 79
SE - Svezia 73
FR - Francia 67
HK - Hong Kong 57
UA - Ucraina 46
FI - Finlandia 24
ZA - Sudafrica 24
ES - Italia 22
CA - Canada 17
BD - Bangladesh 15
KR - Corea 15
MX - Messico 11
IN - India 10
PL - Polonia 7
AR - Argentina 6
CO - Colombia 6
JP - Giappone 6
AZ - Azerbaigian 5
NL - Olanda 5
PK - Pakistan 5
AT - Austria 4
IQ - Iraq 4
TR - Turchia 4
BE - Belgio 3
CR - Costa Rica 3
EC - Ecuador 3
LT - Lituania 3
MY - Malesia 3
NP - Nepal 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
BG - Bulgaria 2
BH - Bahrain 2
CH - Svizzera 2
GT - Guatemala 2
HR - Croazia 2
ID - Indonesia 2
IL - Israele 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
AU - Australia 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CL - Cile 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
EG - Egitto 1
GR - Grecia 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
MK - Macedonia 1
MU - Mauritius 1
PH - Filippine 1
PY - Paraguay 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TL - Timor Orientale 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VE - Venezuela 1
Totale 4.296
Città #
Fairfield 232
Dublin 213
Singapore 200
Southend 182
Ashburn 174
Dallas 144
San Jose 127
Woodbridge 100
Moscow 95
Houston 94
Cambridge 91
Seattle 89
Santa Clara 85
Beijing 79
Wilmington 78
Hong Kong 57
Milan 56
Siena 50
Jacksonville 44
Chandler 40
Ann Arbor 39
Council Bluffs 34
Princeton 33
The Dalles 31
Los Angeles 30
New York 29
Shanghai 29
Ho Chi Minh City 25
Lauterbourg 22
Johannesburg 21
Helsinki 19
Rome 19
San Mateo 18
Málaga 17
Hanoi 15
Dearborn 14
San Diego 13
Hefei 12
Dong Ket 11
Munich 11
Nanjing 11
San Francisco 10
Florence 9
Buffalo 8
Denver 8
Brooklyn 7
Düsseldorf 7
Montreal 7
Orem 7
Palermo 7
Phoenix 7
Seoul 7
Stockholm 7
São Paulo 7
Boston 6
Chicago 6
London 6
Poplar 6
Yongsan-gu 6
Atlanta 5
Avon 5
Baku 5
Columbus 5
Frankfurt am Main 5
Nanchang 5
Toronto 5
Venezia 5
Warsaw 5
Da Nang 4
Figino 4
Labico 4
Mexico City 4
Naples 4
Norwalk 4
Porto Alegre 4
Redondo Beach 4
Tokyo 4
Amsterdam 3
Asciano 3
Boardman 3
Bogotá 3
Bologna 3
Brussels 3
Dhaka 3
Guangzhou 3
Kunming 3
Ninh Bình 3
Pistoia 3
Portsmouth 3
Redwood City 3
Rio de Janeiro 3
Riyadh 3
Tashkent 3
Vienna 3
Abuja 2
Ankara 2
Araras 2
Bari 2
Barnet 2
Benito Juarez 2
Totale 2.955
Nome #
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 366
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 340
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 285
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 276
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 268
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 258
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 246
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma 219
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 209
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 202
Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies 199
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 196
Immunotherapy targeting immune check-point(s) in brain metastases 192
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 187
Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma 184
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 173
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 155
ICOS expression as immunologic marker in immune activating monoclonal antibodies 155
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study 131
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 130
Totale 4.371
Categoria #
all - tutte 13.641
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.641


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022179 0 0 0 5 11 12 14 14 13 32 28 50
2022/2023265 19 22 50 20 9 45 10 28 16 18 15 13
2023/2024318 11 7 52 12 7 72 121 4 0 0 14 18
2024/2025520 15 24 57 21 73 37 4 20 92 17 54 106
2025/20261.478 93 125 106 206 430 67 152 38 23 62 42 134
2026/2027235 59 33 88 55 0 0 0 0 0 0 0 0
Totale 4.371